Barclays analyst Gena Wang lowered her price target for Clovis Oncology to $40 citing “disappointing” Rubraca revenue in Q3. Even considering the drawdown of inventory and increase in free drug giveaways in Q3, the adoption of Rubraca in second-line ovarian maintenance setting still appears slow, Wang tells investors in a research note. The analyst, however, remains constructive in the prospect of expanding Rubraca use into additional settings/indications such as prostate/bladder cancers. She maintains an Overweight rating on Clovis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.